Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib and Nivolumab in TFE/Translocation Renal Cell Carcinoma
NCT03595124Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2019
- Primary completion
- Sep 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of axitinib, nivolumab in renal cell carcinoma (RCC), sponsored by National Cancer Institute. Started Jan 2019; status: active, not recruiting.
02
Drugs
axitinibnivolumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03595124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03595124.